|
|
The
Electro-Chemical & Cancer Institute developed a cancer vaccine in
1946, the Hasumi Vaccine, and started its clinical application in
1948. The research originated within a methodological question:
"How can we let our body's immune mechanisms distinguish cancer
cells from normal cells?" At the time, the late Dr. Kiichiro Hasumi
asserted the hypothesis of a cancer virus as the premise of his
research, a premise that was totally rejected by the medical circle
of Japan at that time. 
Since
1988, the present organization has made efforts to extract membrane
antigen from cancer cells. In 2000, through joint research with
the University of Maryland (USA), the physiological activity of
the Hasumi Vaccine was demonstrated and has paved the way for the
cancer vaccine to steadily prevail. In 1999, through joint research
with the Jefferson Medical College of Thomas Jefferson University
(USA), the clinical research of dendritic cell vaccine, a new type
of cancer vaccine, was started. Moreover, through joint research
with Changchun College of Traditional Chinese Medicine (China) and
Saitama Medical College (Japan), Shukokai Incorporated has developed
an anti-cancer traditional Chinese medicine. In addition, we are
conducting research on the reduction of side effects of anti-cancer
pharmaceuticals as well as on the anti-cancer effects of Chinese
traditional medicines. 
●Chief Cooperative Research Facilities:
University of Maryland, USA
Thomas Jefferson University, USA
Changchun College of Traditional Chinese Medicine, China
Jilin Provincial Cancer Hospital, China
Saitama Medical School, Japan
Medical Research Institute, University of Tokyo, Japan
Graduate School of Engineering, University of Tokyo, Japan
Tokai University, Japan Teikyo University, Japan
This list represents only a partial listing of cooperating facilities
|
Hasumi Vaccine The Hasumi Vaccine has been in clinical use since 1948. At first, the concept of this vaccine was based on the simple premise and a methodological question: "How we can let the body's immune system distinguish cancer cells from normal cells?" In those days, the research was based on the theory of virus-induced cancer propagation, an idea totally rejected by the then reigning medical circle of Japan. We have been making efforts to extract membrane antigen from cancer cells since 1988. In the 1990s the evidence that Dendritic cells, a part of white cells, play a major role in recognizing cancer cells' antigen was demonstrated in the US. In 2000, through a joint research project with the University of Maryland (USA), the physiological activity of the Hasumi Vaccine as a cancer vaccine was proven. This enabled the Hasumi Vaccine to be appreciated on an objective basis. Highly motivated by the positive results, clinical investigation of the Hasumi Vaccine has expanded internationally. |
Electro-Chemical & Cancer Institute
5-45-6 Kokuryo-cho, Chofu, Tokyo 182-0022 Japan
Tel:0424-82-2037 Fax:0424-86-6452
2003 Shukokai Inc.
